EN DE
Watch CMG Pharmaceutical Co. Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

CMG Pharmaceutical Co. Ltd (058820) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of CMG Pharmaceutical Co. Ltd stock KRW 3,800, price KRW 3,625, upside +4.8%, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7058820002

CP CMG Pharmaceutical Co. Ltd logo Thin data Nov 16, 2026

CMG Pharmaceutical Co. Ltd

058820 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Revenue last quarter +25% vs. a year ago. 
Fair value 3,800 KRW · Fairly valued 
Expensive Growth (revenue 5y +10.3 %/yr in KRW) 
Thin margins · 4.0% net margin (TTM) 
Mixed vs. peers (5/11) 
Quality 30/100 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 19/100 · thin data
Thin data 
Estimate
Watch CMG Pharmaceutical Co. Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

55,100 KRW 3,625 KRW Fair Value 3,800 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 3,625 KRW – 55,100 KRW · fair‑value band 2,850 KRW – 4,750 KRW · the 3,625 KRW price screens below the 3,800 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow CMG Pharmaceutical Co. in your weekly email

Every Wednesday you see whether CMG Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea.

Show moreShow less

It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis.

CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013.

CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

Stock analysis

CMG Pharmaceutical Co. Ltd (058820) currently trades at 3,625 KRW, while our estimate is 3,800 KRW, so the stock looks roughly fairly valued today (gap 4.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,850 KRW (bear) to 4,750 KRW (bull), the price of 3,625 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CMG Pharmaceutical Co. Ltd reported revenue of 105B KRW in FY2025 versus 69.5B KRW in FY2021, a compound +10.9%/yr. Reported net income was −10.1B KRW in FY2025.

Key figures

Market cap 70.7B KRW (≈ $53.0M) Micro · P/E ratio 15.9 · P/S ratio 0.61 · EPS (TTM) 313.26 KRW · Net margin −9.6% · Return on equity 2.3% · Return on assets (EBIT) 1.1% (5-year average) · Operating margin −10.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 5%, 058820 screens cheaper than that median.

Fair Value

Bear 2,850 KRW Fair Value 3,800 KRW Bull 4,750 KRW
Price 3,625 KRW · Upside +4.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 41
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +14.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.9% (2020) → −3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 058820, get fair value alerts →

Compare CMG Pharmaceutical Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside +4.8% · Above median
Profitability
Return on equity (12 months) 2.3% · Below median
Return on assets −3.3% · Below median
Net margin (12 months) 4.0% · Below median
Operating margin (12 months) −10.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 24.7% · Top 25%
Balance sheet
Debt / equity 0.18× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 15.9× · Cheaper than median
P/B 0.35× · Cheapest 25%
P/S (12 months) 0.61× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)40 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)9 · sector 26
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.48 $113.53 +36% vs 058820
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.90 ¥52.43 +12% vs 058820
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,872 ₹1,983 +6% vs 058820
Haleon plc HLN $9.05 $8.47 −6% vs 058820
Merck KGaA MRK €149.50 €108.83 −27% vs 058820
Galderma Group GALD CHF 187.55 CHF 112.46 −40% vs 058820
Takeda Pharmaceutical Company TAK $21.64 $11.23 −48% vs 058820
Sandoz Group SDZ CHF 81.50 CHF 40.91 −50% vs 058820
Teva Pharmaceutical Industries Limited TEVA $42.62 $20.74 −51% vs 058820
Divi's Laboratories Limited DIVISLAB ₹11,049 ₹1,567 −86% vs 058820

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CMG Pharmaceutical Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CMG Pharmaceutical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/058820

Frequently asked questions

Is CMG Pharmaceutical Co. Ltd (058820) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 3,800 KRW versus a price of 3,625 KRW, about +5% upside (fairly valued).
What is the fair value of 058820?
Our estimate for CMG Pharmaceutical Co. Ltd is 3,800 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 3,625 KRW.
What is the quality score of 058820?
CMG Pharmaceutical Co. Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CMG Pharmaceutical Co. Ltd (058820)?
Our calculated price target is the estimate of 3,800 KRW (as of Nov 16, 2026). Cautious scenario 2,850 KRW, optimistic scenario 4,750 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CMG Pharmaceutical Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 3,800 KRW, about +5% upside versus a price of 3,625 KRW (fairly valued). Cautious scenario 2,850 KRW, optimistic scenario 4,750 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CMG Pharmaceutical Co. Ltd (058820)?
CMG Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 116B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of CMG Pharmaceutical Co. Ltd (058820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CMG Pharmaceutical Co. Ltd it is 3,800 KRW per share (as of Nov 16, 2026), against a price of 3,625 KRW.
Is CMG Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 058820 trades below its calculated fair value: price 3,625 KRW, fair value 3,800 KRW, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 058820?
No. The price is what the market pays today (3,625 KRW); the fair value is what the company's own numbers justify (3,800 KRW). For CMG Pharmaceutical Co. Ltd the two are 175.39 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CMG Pharmaceutical Co. Ltd worth?
The market values CMG Pharmaceutical Co. Ltd at about 70.7B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 3,625 KRW; our models calculate a fair value of 3,800 KRW per share.
What do the bullish and bearish scenarios say about 058820?
Our models span a range for CMG Pharmaceutical Co. Ltd: cautious scenario 2,850 KRW, base 3,800 KRW, optimistic 4,750 KRW per share (as of Nov 16, 2026, price 3,625 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 058820?
CMG Pharmaceutical Co. Ltd trades at a price-to-earnings ratio of 15.9 (as of Nov 16, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3,800 KRW is built from several models across several years. Other multiples: P/B 0.4, P/S 0.6.
How solid is the balance sheet of CMG Pharmaceutical Co. Ltd (058820)?
Balance-sheet figures for CMG Pharmaceutical Co. Ltd (as of Nov 16, 2026): return on equity 2.3%, debt of 0.18 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 058820 from its 52-week high?
CMG Pharmaceutical Co. Ltd trades at 3,625 KRW, about 83% below its 52-week high of 21,400 KRW and at the low of 3,625 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 3,800 KRW is for.
Which stocks are comparable to CMG Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CMG Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 3,625 KRW, calculated fair value 3,800 KRW (+5%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. CMG Pharmaceutical Co. Ltd currently trades 5% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CMG Pharmaceutical Co. Ltd (058820)?
The closing price on Nov 18, 2026 was 3,625 KRW. Our estimate is 3,800 KRW, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CMG Pharmaceutical Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CMG Pharmaceutical Co. Ltd

How large is the market capitalisation of CMG Pharmaceutical Co. Ltd (058820)?
The market capitalisation of CMG Pharmaceutical Co. Ltd is 70.7B KRW (≈ $53.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CMG Pharmaceutical Co. Ltd (058820)?
The price-to-sales ratio of CMG Pharmaceutical Co. Ltd is 0.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CMG Pharmaceutical Co. Ltd (058820)?
Earnings per share at CMG Pharmaceutical Co. Ltd are 313.26 KRW (price ÷ EPS = P/E 15.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CMG Pharmaceutical Co. Ltd (058820)?
The net margin of CMG Pharmaceutical Co. Ltd is −9.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CMG Pharmaceutical Co. Ltd (058820)?
The return on equity (ROE) of CMG Pharmaceutical Co. Ltd is 2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CMG Pharmaceutical Co. Ltd (058820)?
On an EBIT basis the return on assets of CMG Pharmaceutical Co. Ltd is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CMG Pharmaceutical Co. Ltd (058820)?
The operating margin of CMG Pharmaceutical Co. Ltd is −10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CMG Pharmaceutical Co. Ltd (058820)?
Revenue at CMG Pharmaceutical Co. Ltd is growing 24.7% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CMG Pharmaceutical Co. Ltd (058820)?
Earnings per share at CMG Pharmaceutical Co. Ltd are growing 6.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CMG Pharmaceutical Co. Ltd (058820) generate?
The free cash flow of CMG Pharmaceutical Co. Ltd is −44.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CMG Pharmaceutical Co. Ltd (058820) carry?
The net debt of CMG Pharmaceutical Co. Ltd is 65.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CMG Pharmaceutical Co. Ltd in the live analysis

One click puts CMG Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.